Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články
PubMed
26516201
DOI
10.1126/science.aad0779
PII: science.aad0779
Knihovny.cz E-zdroje
- MeSH
- adjuvantní chemoterapie MeSH
- alely MeSH
- annexin A1 metabolismus farmakologie MeSH
- antracykliny terapeutické užití MeSH
- dendritické buňky účinky léků imunologie MeSH
- jednonukleotidový polymorfismus MeSH
- kolorektální nádory farmakoterapie imunologie MeSH
- leukocyty účinky léků imunologie MeSH
- lidé MeSH
- myši MeSH
- nádorové buněčné linie MeSH
- nádory prsu farmakoterapie imunologie MeSH
- nádory farmakoterapie imunologie MeSH
- přirozená imunita genetika MeSH
- receptory pro formylované peptidy genetika fyziologie MeSH
- T-lymfocyty imunologie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- annexin A1 MeSH
- antracykliny MeSH
- FPR1 protein, human MeSH Prohlížeč
- Fpr1 protein, mouse MeSH Prohlížeč
- receptory pro formylované peptidy MeSH
Antitumor immunity driven by intratumoral dendritic cells contributes to the efficacy of anthracycline-based chemotherapy in cancer. We identified a loss-of-function allele of the gene coding for formyl peptide receptor 1 (FPR1) that was associated with poor metastasis-free and overall survival in breast and colorectal cancer patients receiving adjuvant chemotherapy. The therapeutic effects of anthracyclines were abrogated in tumor-bearing Fpr1(-/-) mice due to impaired antitumor immunity. Fpr1-deficient dendritic cells failed to approach dying cancer cells and, as a result, could not elicit antitumor T cell immunity. Experiments performed in a microfluidic device confirmed that FPR1 and its ligand, annexin-1, promoted stable interactions between dying cancer cells and human or murine leukocytes. Altogether, these results highlight the importance of FPR1 in chemotherapy-induced anticancer immune responses.
Department of Hematology Oncology and Molecular Medicine Istituto Superiore di Sanità Rome Italy
Department of Life Sciences University of Siena Siena Italy
Genomics and Immunoregulation Life and Medical Science Center Institute University of Bonn Germany
Gustave Roussy Cancer Campus Villejuif France INSERM U981 Villejuif France
Italian National Research Council Institute for Photonics and Nanotechnology Rome Italy
Citace poskytuje Crossref.org
Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma
Detection of immunogenic cell death and its relevance for cancer therapy
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy
